Semaglutide

Semaglutide

Semaglutide is the active ingredient in several products with different approved uses and instructions. Wegovy provides weight-management options. Ozempic injection and Ozempic tablets/Rybelsus are diabetes products. Choosing a product requires more than choosing the ingredient.

How semaglutide works

Semaglutide activates the GLP-1 receptor. It affects appetite, slows stomach emptying, and helps glucose regulation. The brand, route, dose, and diagnosis determine the approved use. Tablets and injections cannot be exchanged milligram for milligram.

Eligibility: Semaglutide

Wegovy injection includes adults with obesity, selected adults with overweight, and children 12 and older with obesity. Wegovy tablets have adult indications. Ozempic products treat adults with type 2 diabetes, with additional product-specific indications. Compounded products are not FDA-approved equivalents.

What to expect: Semaglutide

Review whether the goal is diabetes, weight, cardiovascular risk, or qualifying MASH care. Select the exact approved product, review medical risks and insurance requirements, and teach its use. Set a nutrition and monitoring plan. A switch or restart after an interruption needs prescriber review.

Preparing for your appointment

Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.

Risks and when to seek help

Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. For weight treatment, stop semaglutide at least two months before a planned pregnancy with prescriber guidance. Do not buy “research use only” products or assume compounded concentrations and syringe units are interchangeable.

Follow-up and treatment review

Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.

Appointments, costs and coverage

Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.

Medical sources

• wegovy current US prescribing information
• ozempic-injection current US prescribing information
• ozempic-tablets-rybelsus current US prescribing information
• NIDDK prescription weight-management medicines
• FDA unapproved GLP-1 drugs, salt forms and compounding concerns
• foundayo current US prescribing information
• zepbound current US prescribing information
• Illinois HFS Rybelsus to Ozempic tablet transition notice
• NIDDK healthy eating and activity
• Recognizing medical emergencies: MedlinePlus Medical Encyclopedia